Nardin Nakhla ^UDM

Nardin Nakhla, a co-founder at Simmunome AI, addresses the inefficiency of clinical trial success, leveraging AI to unravel biological complexity. Simmunome transforms physiological systems into biologically representative computational models for therapeutic and preventative drug discovery. The company combines fragmented data to create holistic disease models, enhancing understanding of drug mechanisms, increasing efficacy, and predicting safety profiles. Simmunome AI's approach aims to accelerate time to market, reduce R&D costs, and increase the probability of success, contributing to more impactful medicines.